Recent advances of DNAzyme-based nanotherapeutic platform in cancer gene therapy

• 来源期刊: 生物物理学报
• 年，卷（期）: 2020,（6）
• 所属期刊栏目: REVIEW
• 页码范围: 256-265
• 页数: 10页
• 语种: 中文
• DOI: 10.3969/j.issn.1000-6737.2020.06.003

摘要

Deoxyribozyme(or denoted as DNAzyme),which is produced by in vitro screening technology,has gained extensive research interest in the field of biomedicine due to its high catalytic activity and structure identification.This review introduces the structural characteristics of RNA-cleaving DNAzyme and its application potential in cancer gene therapy,which plays a significant role in cancer-related gene inactivation by specifically cleaving target mRNA and inhibiting the expression of the corresponding protein.However,the low delivery efficiency and cellular uptake hindered the widespread usage of DNAzyme in gene therapy of cancers.Emerging nanotechnology holds great promise for DNAzyme to overcome these obstacles.This review mainly focuses on DNAzyme-based nanotherapeutic platforms in gene therapy of cancers,including oncogene antagonism therapy,treatment resistance gene therapy,immunogene therapy,and antiangiogenesis gene therapy.We also revealed the potential of DNAzyme-based nanotherapeutic platforms as emerging cancer therapy approaches and their security issues.